Welcome to our dedicated page for Microbot Med news (Ticker: MBOT), a resource for investors and traders seeking the latest updates and insights on Microbot Med stock.
Microbot Medical develops and distributes the LIBERTY Endovascular Robotic System, an FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures. Company news centers on the system’s U.S. commercialization, adoption by healthcare institutions, use across peripheral endovascular case types, and clinical evidence from the ACCESS-PVI pivotal study.
Updates also cover medical-society guidance on radiation exposure and ergonomics in interventional radiology, conference presentations to healthcare and financial audiences, and commercial readiness outside the United States. The company frames LIBERTY around robotic vascular navigation and the need to address radiation exposure and physical strain for interventional teams.
Microbot Medical Inc. (NASDAQ: MBOT) announced key developments for its LIBERTY® Robotic System during the H.C. Wainwright 24th Annual Global Investment Conference on September 13, 2022. CEO Harel Gadot highlighted the commencement of the GLP pre-clinical trial and provided an overview of the company's progress and future plans. Microbot Medical focuses on advanced micro-robotic technologies targeted at improving patient outcomes and accessibility in medical treatments. The presentation is available for viewing on their official website.
Microbot Medical Inc. (Nasdaq: MBOT) has launched its GLP Pre-Clinical Trial for the LIBERTY Robotic System at a renowned MedTech research institute. This trial marks a significant milestone in the company’s journey toward regulatory approvals. CEO Harel Gadot believes that successful feasibility studies will enable them to meet the trial's endpoints and further pursue regulatory approvals in the surgical robotics sector, particularly in endovascular applications. This move underscores Microbot's focus on innovative micro-robotic technologies aimed at enhancing clinical outcomes.
Microbot Medical (NASDAQ: MBOT) announced the appointment of Dr. Sebastian Flacke to its Scientific Advisory Board, enhancing its expertise in the endovascular space. Dr. Flacke, a pioneer in robotic solutions and interventional radiology, will guide the company through crucial regulatory processes and commercialization efforts for the LIBERTY® Robotic System. This system aims to be the first fully disposable endovascular robotic platform, improving patient access globally. CEO Harel Gadot emphasized Dr. Flacke's innovative contributions, signaling strong leadership for future developments.
Microbot Medical Inc. (Nasdaq: MBOT) has received two Design Patent Applications grants from the European Patent Office, enhancing its LIBERTY® Robotic System’s IP portfolio. This recognition underscores the innovative aspects of the LIBERTY Robotic System, providing a sustainable competitive advantage in the medical device sector. CEO Harel Gadot emphasized that expanding their IP will support their vision for broader accessibility to robotic technologies, benefiting physicians and patients alike.
Microbot Medical (NASDAQ: MBOT) has shipped multiple LIBERTY Robotic System devices for a GLP pre-clinical trial, scheduled to start this month, at a leading research laboratory. This initiative is part of the company's preparations for FDA and CE Mark submissions. CEO Harel Gadot expressed optimism about their collaboration with top experts, indicating that the trial results will validate prior successful animal studies.
Microbot Medical Inc. (Nasdaq: MBOT) will present its Self-Cleaning Shunt (SCS) at the 16th Asian Australasian Congress of Neurological Surgeons from September 6-8, 2022, in Jerusalem, Israel. The presentation will be led by Dr. Gustavo Rajz during the Neuro Innovation and Start-Up Symposium on September 7. The SCS aims to prevent cerebrospinal fluid obstructions in patients with hydrocephalus and has received FDA approval for an Early Feasibility Study. For further inquiries or demonstrations, contact the company via email.
Microbot Medical (NASDAQ: MBOT) will present at the Annual Needham Virtual Healthcare Conference on April 12, 2022, at 8:45 AM ET. Harel Gadot, the Chairman, President, and CEO, will discuss the company and its recent progress. This event can be accessed via the 'Investors' section on their website. Microbot Medical focuses on transformational micro-robotic technologies for both natural and artificial lumens in the human body, aiming to improve patient outcomes and accessibility since its founding in 2010.
Microbot Medical Inc. (Nasdaq: MBOT) has appointed Rachel Vaknin as its new Chief Financial Officer, effective April 1, 2022, replacing David Ben Naim. With over 20 years of finance experience, Ms. Vaknin aims to enhance the company's financial planning, analysis, and investor relations. Her previous roles include CFO in the autonomous driving sector and various positions at Mellanox Technologies. The management views this leadership change as a strategic move to support commercialization efforts and reinforce operational goals.
Microbot Medical Inc. (NASDAQ: MBOT) has successfully filed a pre-submission package for its LIBERTY® Robotic System with the FDA, keeping on track with its Q1 timeline. The company is set to meet the FDA to align on testing protocols and regulatory pathways, indicating a proactive approach towards gaining clearance. CEO Harel Gadot expressed confidence in the company's progress and readiness to enhance its organizational infrastructure to support future commercial endeavors.
Microbot Medical (Nasdaq: MBOT) has announced a strategic collaboration with Stryker’s Neurovascular division to integrate its neurovascular instruments with the LIBERTY Robotic System. This partnership aims to create the first dedicated robotic procedural kits for specific neurovascular procedures, enhancing the competitive edge of the LIBERTY system. The company will maintain independent development for the LIBERTY system in peripheral and coronary procedures. Animal studies suggest this innovation could enable safer, more efficient remote catheter-based procedures, potentially reducing risks for healthcare professionals.